Record: 1

06/04/2024

Daily Note

Pages: 4

Atumelnant Wows at ENDO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Record: 2

05/23/2024

Daily Note

Pages: 3

Positive Initial Data From Atumelnant Phase 2 Study Suggests Another Winner for Crinetics; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Record: 3

05/10/2024

Company Report

Pages: 5

Paltusotine NDA Submission On Track, Eyes On Phase 2 Results Of Atumelnant at ENDO

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Record: 4

04/05/2024

Industry Report

Pages: 6

Long Overlooked, Graves? Disease Goes In Vogue With New Approaches

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Record: 5

03/20/2024

Company Report

Pages: 5

Paltusotine Sets the New Standard in Acromegaly; We Raise Our Price Target to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Record: 6

03/19/2024

Daily Note

Pages: 3

Paltusotine Aces PATHFNDR-2 and Clears the Path to Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Record: 7

03/13/2024

Daily Note

Pages: 4

With Positive Carcinoid Syndrome Data Confirmed, Paltusotine Looks to Phase 3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Record: 8

03/08/2024

Company Report

Pages: 5

Eyes on PATHFNDR-2 Readout This Month; Raise Price Target to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Record: 9

01/19/2024

Company Report

Pages: 39

Setting Expectations For PATHFNDR-2; A Comprehensive Slide Deck

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 75.00

Record: 10

12/19/2023

Company Report

Pages: 5

Paltusotine Comes Up Aces Again; Price Target Up to $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Record: 11

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for CRNX 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Record: 12

11/08/2023

Company Report

Pages: 5

3Q Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Record: 13

09/14/2023

Daily Note

Pages: 5

Tens Across the Board for Paltusotine in PATHFNDR-1; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Record: 14

09/11/2023

Daily Note

Pages: 4

Paltusotine Aces PATHFNDR-1; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Record: 15

08/11/2023

Daily Note

Pages: 4

Top Takeaways from KOL Webinar on Acromegaly

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Record: 16

08/09/2023

Company Report

Pages: 5

Enthusiasm For Paltusotine is Clear With Readout on Deck; Adjusting PT to $33 With Setback for CHI Program; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Record: 17

06/20/2023

Daily Note

Pages: 6

Takeaways from our Conversation with Crinetics Pharmaceuticals and ENDO 2023; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Record: 18

06/08/2023

Company Report

Pages: 43

Previewing PATHFNDR Readouts For Paltusotine; A Comprehensive Slide Deck

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Record: 19

06/06/2023

Industry Report

Pages: 4

Emerging Ideas in Biopharma Call Series

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Record: 20

05/05/2023

Company Report

Pages: 5

Resizing for PATHFNDR-2 Bodes Well for Paltusotine; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00